Skip to main content
    S

    Sangamo Therapeutics Inc (SGMO)

    Official site

    BIOTECHNOLOGY

    $0.07
    +0.00 (+0.00%)

    Last updated: Oct 13, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(20/38)
    Avg Surprise
    -4.16%

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.04-25.0%
    60d ago$-0.04-25.0%
    30d ago$-0.07+23.1%
    7d ago$-0.07+23.1%
    Current$-0.05
    Revenue Consensus
    $10M
    Range$0 - $27M
    4 analysts
    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.04-42.9%
    60d ago$-0.04-42.9%
    30d ago$-0.07+28.6%
    7d ago$-0.07+28.6%
    Current$-0.05
    Revenue Consensus
    $9M
    Range$0 - $29M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.03---
    Sep 26EST
    		-$-0.05---
    Jun 26EST
    		-$-0.05---
    Mar 26
    Reported May 14
    		$-0.08$0.04-300.00%Miss+42.9%
    Dec 25
    Reported Mar 30
    		$-0.07$-0.01-446.97%Miss+34.4%
    Sep 25
    Reported Nov 6
    		$-0.11$-0.10-10.00%Miss-375.0%
    Jun 25
    Reported Aug 7
    		$-0.08$-0.12+33.33%Beat+52.9%
    Mar 25
    Reported May 12
    		$-0.14$-0.13-7.69%Miss+44.0%
    Dec 24
    Reported Mar 17
    		$-0.11$-0.09-21.01%Miss+67.6%
    Sep 24
    Reported Nov 12
    		$0.04$-0.04+200.00%Beat+112.1%
    Jun 24
    Reported Aug 6
    		$-0.17$-0.16-6.25%Miss+55.3%
    Mar 24
    Reported May 9
    		$-0.25$-0.24-4.17%Miss-308.3%
    Dec 23
    Reported Mar 13
    		$-0.34$-0.26-30.77%Miss-6.3%
    Sep 23
    Reported Nov 1
    		$-0.33$-0.29-13.79%Miss+2.9%
    Jun 23
    Reported Aug 8
    		$-0.38$-0.32-18.75%Miss-31.0%
    Mar 23
    Reported Apr 27
    		$0.12N/A+136.36%Beat+140.0%
    Dec 22
    Reported Feb 22
    		$-0.32$-0.36+11.11%Beat-23.1%
    Sep 22
    Reported Nov 3
    		$-0.34$-0.36+5.56%Beat-3.0%
    Jun 22
    Reported Aug 4
    		$-0.29$-0.34+14.71%Beat+12.1%
    Mar 22
    Reported May 5
    		$-0.30$-0.29-3.45%Miss+6.3%
    Dec 21
    Reported Feb 24
    		$-0.26$-0.35+25.71%Beat+10.3%
    Sep 21
    Reported Nov 4
    		$-0.33$-0.33+0.00%Beat-3200.0%
    Jun 21
    Reported Aug 5
    		$-0.33$-0.31-6.45%Miss-26.9%
    Mar 21
    Reported May 4
    		$-0.32$-0.29-10.34%Miss+13.5%
    Dec 20
    Reported Feb 24
    		$-0.29$-0.21-38.10%Miss-514.3%
    Sep 20
    Reported Nov 4
    		$-0.01N/A+96.00%Beat+95.8%
    Jun 20
    Reported Aug 5
    		$-0.26$-0.34+23.53%Beat+0.0%
    Mar 20
    Reported May 11
    		$-0.37$-0.35-5.71%Miss+9.8%
    Dec 19
    Reported Feb 28
    		$0.07N/A+121.21%Beat+138.9%
    Sep 19
    Reported Nov 6
    		$-0.24$-0.34+29.41%Beat-84.6%
    Jun 19
    Reported Aug 7
    		$-0.26$-0.35+25.71%Beat-52.9%
    Mar 19
    Reported May 8
    		$-0.41$-0.24-70.83%Miss-78.3%
    Dec 18
    Reported Feb 28
    		$-0.18$-0.21+14.29%Beat-20.0%
    Sep 18
    Reported Nov 8
    		$-0.13$-0.18+27.78%Beat+13.3%
    Jun 18
    Reported Aug 8
    		$-0.17$-0.15-13.33%Miss+0.0%
    Mar 18
    Reported May 8
    		$-0.23$-0.18-27.78%Miss+0.0%
    Dec 17
    Reported Feb 22
    		$-0.15$-0.18+16.67%Beat-7.1%
    Sep 17
    Reported Nov 9
    		$-0.15$-0.19+21.05%Beat-
    Jun 17
    Reported Aug 9
    		$-0.17$-0.22+22.73%Beat-
    Mar 17
    Reported May 10
    		$-0.23$-0.25+8.00%Beat-
    Dec 16
    Reported Feb 28
    		$-0.14$-0.25+44.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.22EV/EBITDAN/A
    Price/FCF-0.32xFCF Yield-313.74%
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROIC-29534.16%
    Financial Health
    Debt/Equity-1.02xInterest CoverageN/A
    Current Ratio0.70xQuick Ratio0.70x
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.07
    SMA 20$0.07
    SMA 50$0.07
    SMA 200$0.21
    EMA 10$0.07
    EMA 20$0.07
    EMA 50$0.08
    EMA 200$0.20

    MACD

    Line: -0.00Signal: -0.00Hist: 0.00

    ADX

    ADX: 33.0+DI: 17.1-DI: 34.0

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down100.0
    PSAR$0.07

    Bollinger Bands

    Upper Band$0.07
    Lower Band$0.07
    %B PositionN/A
    Band Width0.06

    RSI (14-Day)

    Oversold
    27.9

    Momentum Oscillators

    Stoch %KN/A
    Stoch %DN/A
    Williams %RN/A
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)N/A
    MFI (14d)N/A

    Volatility Measures

    ATR (14d)$0.00(0.2%)
    StdDev (20d)N/A
    Hist VolN/A

    Volume Flow

    VWAP$0.07
    OBV-102.0M
    AD Line-292.3M
    CMF (20d)N/A

    Volume Metrics

    Avg Vol (20d)N/A
    Vol RatioN/A
    VWMA (20d)N/A

    Pivot Points

    R3$0.07
    R2$0.07
    R1$0.07
    Pivot Point$0.07
    S1$0.07
    S2$0.07
    S3$0.07

    Advanced Oscillators

    TSI-46.37
    Ultimate OscN/A
    KSTN/A

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$1.44M$14.23M$581,000$18.31M$6.44M$7.55M$49.41M$356,000$481,000$2.04M$9.40M$6.83M
    Cost of RevenueN/A$1.88M$1.90MN/AN/A$2.13M$2.13M$2.57M$2.53M$2.98M$57.09M$59.25M
    Gross Profit$1.44M$14.23M$581,000$18.31M$6.44M$7.55M$49.41M$356,000$481,000$2.04M$-47,691,000$-52,411,000
    Operating Expenses$33.39M$39.20M$36.13M$36.16M$36.06M$33.54M$38.78M$37.44M$52.01M$64.10M$58.72M$71.16M
    R&D$26.57M$31.44M$28.14M$27.08M$26.01M$23.68M$27.73M$24.22M$35.89M$50.71M$57.09M$63.05M
    SG&A$6.82M$7.76M$7.99M$9.08M$10.06M$9.87M$11.05M$12.04M$11.77M$13.10M$13.92M$14.81M
    Operating Income$-31,946,000$-24,968,000$-35,553,000$-17,855,000$-29,628,000$-25,990,000$10.63M$-37,084,000$-51,526,000$-62,059,000$-106,408,000$-123,572,000
    Interest Income$300,000$252,000$355,000$386,000$309,000$2.17M$129,000$416,000$451,000$1.49M$3.52M$0
    Interest Expense$0$13.00M$0$2.10M$850,000$0$0$0$0$113.85M$0$0
    Income Before Tax$-30,995,000$-37,972,000$-35,091,000$-19,959,000$-30,478,000$-23,823,000$10.76M$-36,054,000$-48,991,000$-60,567,000$-102,893,000$-120,770,000
    Income Tax Expense$0$-553,000$-161,000$27,000$119,000$-427,000$88,000$74,000$98,000$-272,000$1.27M$-6,264,000
    Net Income$-30,995,000$-37,419,000$-34,930,000$-19,986,000$-30,597,000$-23,396,000$10.67M$-36,128,000$-49,089,000$-60,295,000$-104,163,000$-114,506,000
    EBITDA$-31,069,000$-23,085,000$-33,193,000$-18,062,000$-27,704,000$-23,855,000$12.76M$-33,339,000$-44,651,000$-58,754,000$-56,116,000$-62,969,000
    EBIT$-31,946,000$-24,968,000$-35,091,000$-19,959,000$-29,628,000$-25,990,000$10.63M$-35,912,000$-47,177,000$-61,763,000$-61,609,000$-67,225,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SGMO

    News

    Sangamo Therapeutics Inc Market Sentiment

    This article provides an overview of market sentiment for Sangamo Therapeutics Inc (SGMO), detailing analyst consensus, short interest, options flow...

    Benzinga España•7/29/26•Somewhat-Bearish

    Sangamo Therapeutics, Inc. Revenue Breakdown – DUS:GBY

    This article provides a revenue breakdown for Sangamo Therapeutics, Inc. (GBY) on the Dusseldorf Stock Exchange. It highlights that in the last year, the company generated 33.68 million EUR...

    TradingView•7/28/26•Neutral

    Sangamo Therapeutics, Inc. Revenue Breakdown – OTC:SGMOQ

    Sangamo Therapeutics, Inc. (OTC:SGMOQ) generated $39.55 million in revenue last year, primarily from its Zinc Finger Epigenetic Regulators segment. This represents a decrease from the previous year's revenue of $57.80...

    TradingView•7/26/26•Neutral

    Sangamo looks to switch lenders mid-bankruptcy as it eyes a quick sale process

    Sangamo Therapeutics is seeking to switch lenders during its bankruptcy process to save at least $400,000. This move comes as the company anticipates another month before its assets are liquidated in a quick sale....

    The Business Journals•7/22/26•Bearish

    Sangamo Therapeutics Received Notice of Delisting

    Sangamo Therapeutics (SGMOQ) has received a notice of delisting from Nasdaq. The company's request to continue its listing was denied by Nasdaq's Hearings Panel on July 14, 2026...

    TradingView•7/20/26•Neutral

    SGMO Valuation and Fair Value

    P/E
    -0.2x
    P/FCF
    -0.3x
    P/B
    -1.5x
    See GNG's fair value

    SGMO Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    ROIC
    -29534.2%
    FCF yield
    -313.7%

    SGMO Competitors

    CompanyTicker
    Picard Medical, Inc.PMI
    Evoke Pharma IncEVOK
    Nortech Systems IncorporatedNSYS
    MIRA Pharmaceuticals, Inc. Common StockMIRA
    NextCure IncNXTC
    Transcode Therapeutics IncRNAZ
    DocGo IncDCGO
    OneMedNet Corp.ONMD

    Sector: Healthcare

    SGMO Bull Case vs Bear Case

    Bear case

    • SGMO beat EPS estimates in 25.0% of its last 8 reported quarters.

    SGMO Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -69.8%
    EPS estimate (fiscal period ending Jun 30, 2026)
    $-0.05
    Estimate revisions (30 days, fiscal period ending Jun 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About SGMO

    Does SGMO pay dividends?

    Sangamo Therapeutics Inc (SGMO) does not currently pay a regular dividend.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In